引 致 更 改 給 病 人 的 產 品 資 訊 的 藥 物 不 良 反 應 警 示
|
| |
| The Medicines and Healthcare products Regulatory Agency (MHRA) plans to withdraw orciprenaline sulphate from the UK market following a risk-benefit analysis(English only) |
| |
Orciprenaline sulphate is a medicine used to treat airway obstruction seen in conditions such as asthma. The MHRA recently performed a risk-benefit analysis of orciprenaline sulphate, which considered the data available on its efficacy (compared to other asthma medicines) and safety. The risks associated with orciprenaline sulphate, particularly cardiac adverse reactions such as tachycardia and palpitations, outweigh its clinical benefits. The MHRA concluded that as there are newer medicines available for treating airways obstruction with fewer adverse reactions, orciprenaline sulphate should not continue to be licensed and marketed. Therefore, this medicine will be withdrawn from the market by September 2010. The relevant link for the news is:
http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON062529
Ends/Wednesday, November 4, 2009
Issued at HKT 15:00 |
| |
